An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

Publisher： Karger

E-ISSN： 2296-5262|30|7|355-360

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.7, 2007-06, pp. : 355-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 61-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

By  

Oncology, Vol. 74, Iss. 3-4, 2008-08 ,pp. : 223-228

Karger

Access to resources Recommend Favorite

Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 168-175

Karger

Access to resources Recommend Favorite

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 281-287

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite